Altesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year

Positive

AI Analysis

Summary

Altesa BioSciences secured an oversubscribed $75 million Series B financing round and was recognized with the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year. The Atlanta-based clinical-stage biotech is developing breakthrough therapies targeting chronic lung diseases.

Outcome Details

Oversubscribed $75 million Series B financing

Importance:5/10

Sentiment:

0.70

Series B FinancingGeorgia Life Sciences AwardChronic Lung DiseasesClinical-stage

Related Companies

$IBO

Read the original article

Published by PR Newswire Biotech on August 25, 2026 11:00 AM

Read Original